Cecilia Jones - 11 Jan 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc.

Role
Chief Financial Officer
Signature
/s/ Andrea Paul, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
11 Jan 2022
Net transactions value
-$4,372
Form type
4
Filing time
13 Jan 2022, 17:36:54 UTC
Next filing
03 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LOGC Common Stock Options Exercise +5,939 5,939 11 Jan 2022 Direct F1
transaction LOGC Common Stock Tax liability $4,372 -2,175 -37% $2.01 3,764 12 Jan 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LOGC Restricted Stock Units Options Exercise $0 +5,939 $0.000000* 0 11 Jan 2022 Common Stock 5,939 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
F2 This sale was made automatically by the Company to cover tax withholding obligations in connection with the vesting and settlement of the RSUs reported in the row above. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.03, inclusive.
F3 These RSUs, which represent 100% of the RSUs granted to the Reporting Person that were previously reported for the Reporting Person on a Form 4 filed on January 13, 2021, vested on January 11, 2022, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.

Remarks:

Exhibit List: Exhibit 24.1 Power of Attorney